SION · Sionna Therapeutics, Inc.
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company believes that its existing cash, cash equivalents and marketable securities of $268.3 million as of June 30, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial statements are issued.”View the 10-Q filed Aug 6, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Sep 14, 2026TL;DR. Sionna reported that its Phase 2a Precision CF trial of SION-719 added to Trikafta failed to meet its primary activity endpoint (mean placebo-adjusted sweat chloride change of -1 mmol/L, p=0.7, vs. a targeted ≥10 mmol/L improvement), and the company is discontinuing development of 719 as add-on therapy; the Phase 1 dual combination trial of SION-451 met its safety, tolerability, and PK goals and identified 451+2222 as the preferred dual combination. The company ended Q2 with $268.3M in cash and is taking actions to preserve capital while evaluating next steps for 451+2222.
- + Phase 1 dual combination trial of SION-451 met safety, tolerability, and PK objectives, exceeding target exposures set before the Precision CF readout.
- + 451+2222 selected as preferred dual combination based on favorable tolerability and exposure.
- + Cash position of $268.3M is expected to fund operations into 2028.
- − Company is discontinuing development of SION-719 as an add-on to standard of care.
- − Higher-than-expected variability in sweat chloride and observed differential Trikafta exposure between treatment periods are potential confounders that require further investigation before deciding the 451+2222 path forward.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SION
this stock
Sionna Therapeutics, Inc.
|
$165.93M | -90.6% | — | — | 8.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.15B | +5.7% | +20.8% | 20.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.39B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$65.57B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SION | -6.8% | -24.9% | -91.1% | -26.4% | -90.6% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | -6.8% | -25.6% | -95.9% | -27.4% | -103.5% |